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Abstract 
Background: Deficits in executive functions such as access to semantic/long term memory 
have been shown in ecstasy users in previous research.  Equally, there have been many 
reports of equivocal findings in this area.  The current study sought to further investigate 
behavioural and electrophysiological measures of this executive function in ecstasy users.  
Method: Twenty ecstasy polydrug users, 20 non-ecstasy polydrug users and 20 drug naive 
controls were recruited. Participants completed background questionnaires about their drug 
use, sleep quality, fluid intelligence and mood state.  Each individual also completed a 
semantic retrieval task whilst 64 channel EEG measures were recorded. Results: ANOVA 
revealed no between group differences in behavioural performance on the task. Mixed 
ANOVA on ERP components P2, N2 and P3 revealed significant between group differences 
in the N2 component. Subsequent exploratory univariate ANOVAs on the N2 component 
revealed marginally significant between group differences, generally showing greater 
negativity at occipitoparietal electrodes in ecstasy users compared to drug naïve controls. 
Despite the absence of behavioural differences, differences in N2 magnitude are evidence of 
abnormal executive functioning in ecstasy polydrug users. 
 
Keywords: ecstasy; cannabis; executive function.   
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Introduction 
The recreational drug ecstasy/MDMA (3,4-methylenedioxymethamphetamine) is a 
potent indirect monoaminergic agonist, that is structurally similar to amphetamine and 
mescaline (Morgan, 2000). The acute psychological and physiological effects include 
feelings of euphoria and empathy, increased energy, dilated pupils and tight jaw (trismus) 
(Davison & Parrott, 1997) and are thought to result primarily from serotonin and dopamine 
agonsim (McDowell & Kleber, 1994). However “ecstasy” has been classed under the novel 
pharmacological category of entactogens owing to its unique psychoactive profile that can be 
differentiated from classic hallucinogens and stimulants (Morgan, 2000). 
Cognitive deficits have been reported among ecstasy users, and use is associated with 
working memory and executive functioning impairments (Fisk et al., 2004; Montgomery et 
al., 2008). Areas involved in working memory and executive function include the 
dorsolateral prefrontal cortex (DLPFC) and dependent on the nature of the task, the 
hippocampus. These structures are densely innervated with 5HT neurons (Pazos et al., 1987). 
As such, degradation to the integrity of this system via neurotoxicity or alternatively down-
regulation from prolonged use of the drug, may result in deficits in the cognitive functions 
that these areas maintain. In addition to this, lack of sleep (among other possible lifestyle 
variables, such as heat and bioenergetic stress), has been suggested to exacerbate or even 
cause cognitive deficits observed in ecstasy using populations (Cole et al. 2002).  
Furthermore, Allen et al., (1993) report that characteristics of sleep, such as sleep quality, 
quantity of hours and related changes in alertness are altered in ecstasy users relative to 
controls. More recently, Carhart-Harris et al., (2009) found that current and abstinent ecstasy 
users who reported little use of “other” drugs reported persistent abnormalities in sleep 
patterns and quality. Nonetheless, deficits in memory have been observed to persist after 
controlling for sleep and other lifestyle variables (Montgomery et al., 2010). 
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The central executive of working memory has been suggested to comprise of four 
discrete functions rather than being a unified construct (Miyake, et al., 2000). The initial 
three functions - monitoring and updating of working memory, inhibitory control and mental 
set shifting proposed by Miyake et al. (2000) were supplemented by a fourth component of 
“access” to semantic/long term memory added by Fisk and Sharp (2004). This “access” 
component involves word fluency and the efficiency of lexical access. Retrieval of words and 
semantics involves the ability to access the long term memory store, and the efficiency with 
which this can occur seems to be dependent on areas of the DLPFC (Stuss et al., 1998), as 
well as other subcortical networks (Jokeit et al., 1998). It may not be entirely surprising that 
word fluency requires long term memory activation, and it has been observed that long term 
recall is correlated with performance on word fluency tasks (Ruff et al., 1997). 
Some studies have been conducted that assess access to semantic memory in ecstasy 
users using measures such as the Controlled Oral Word Association task (COWA) in which 
participants have 1 minute to vocalise as many words beginning with F, A and S as possible 
(see Bhattacharay & Powell, 2001). Some studies using this measure have yielded deficits in 
ecstasy users compared to controls (Bhattachary & Powell, 2001; Fox et al. 2002), whereas 
others report no such deficits (e.g. Halpern et al., 2004). However, as a written variant of the 
COWA, the Chicago Word Fluency Test appears to yield more consistent observable deficits 
in ecstasy users (Montgomery et al., 2005; Montgomery et al., 2007). It remains a possibility 
that a verbal one minute retrieval task, with no restrictions upon word type or length is too 
simple to require the involvement of the central executive and as such ecstasy users may not 
show any impairment on the COWA. It has been noted that ecstasy users have shown 
impairments on difficult aspects of tasks, yet appear unaffected on simple tasks that require 
relatively automatic processing (Fox et al., 2002). Consequently further investigation of 
ecstasy related deficits in access to semantic memory is required.   
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Neuroimaging techniques such as electroencephalography, positron electron 
tomography (PET) and functional magnetic resonance imaging (fMRI) are useful tools for 
this type of investigation. Firstly, it would be beneficial to observe neurophysiological 
correlates of behavioural deficits and the underlying mechanisms by which this executive 
function operates. In addition, due to the necessity for neurophysiological techniques to 
reduce body movements and vocalisations so that the data is not contaminated with noise, it 
would be advantageous to develop novel tasks to tap this function as suggested by Murphy et 
al., (2009). Badre et al., (2005) used fMRI to observe the mechanisms by which semantic 
retrieval occurs in healthy controls. Participants were presented with a cue word and 3 target 
words on a screen for 3 seconds. Participants were required to either select a target (by using 
a keyboard) based on a global relation to the cue (i.e. no judgement made about specific 
features or dimensions of the words such as shape, colour, semantics) or alternatively based 
on a specific semantic feature. Stimuli were matched for word length and frequency of 
presentation; furthermore cue-target associative strength was varied. For example a low 
semantic associative strength would have a cue word such as “detective” with targets “search, 
offer and pond” with “search” being the closest to “detective” semantically. An example of 
high associative strength would be “candle” with the targets “flame, arena and goat” and 
here it is clear that candle and flame are strongly associated in meaning and as such represent 
a high associative strength. Badre et al., (2005) posit that prefrontal cortex mechanisms 
mediate semantic retrieval and that the ventrolateral prefrontal cortex (VLPFC) and middle 
temporal cortex are sensitive to association strength. 
Whitney et al., (2010) investigated the neuronal network involved in semantic 
retrieval and processing. Strength of semantic association with the cue word low vs. high was 
used as the manipulation. Transcranial Magnetic Stimulation (TMS) in healthy subjects was 
employed to disrupt processing in the Inferior Frontal Gyrus (IFG) and the posterior middle 
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temporal cortex. Disruption to both of these sites produced attenuation of effective processing  
of executively demanding processes, however processing of cue-target stimuli with strong 
semantic association that are relatively automatic – were unaffected by the disruption.  It was 
concluded that there is a network of prefrontal and posterior temporal regions that underlie 
semantic control, and may provide an explanation why ecstasy users may be unaffected in 
relatively simple semantic retrieval tasks, such as the COWA. 
Indeed electrophyisiological measures such as EEG are more sensitive to detecting 
impairment than behavioural measures alone. For example, certain behavioural differences 
may be undetectable due to compensatory mechanisms that are employed to provide support 
for degraded primary mechanisms. This has been observed in patients with Alzheimer‟s 
disease (Rossi et al., 2004). Additionally, Saykin et al. (1998) investigated semantic retrieval 
in Alzheimer‟s disease patients with the use of neuroimaging, and observed that they 
displayed additional activation in frontal regions compared to controls. This is suggestive of 
compensatory recruitment of additional resources in order to complete the tasks to a similar 
standard of performance to controls. Similarly using fMRI, Kanayama et al., (2004) reported 
that cannabis users displayed activation of additional brain regions to those usually observed 
in a spatial working memory task using fMRI, despite behavioural measures providing no 
observable differences between them and controls. Here, the results from behavioural 
measures would indicate that the processes involved in spatial working memory were intact 
in cannabis users, yet the neuroimaging data suggest recruitment of additional resources.  
Furthermore Jager et al., (2006) has also reported alterations to left superior parietal cortex 
activity on working memory tasks in cannabis users despite equivalent behavioural 
performance to controls on the task. Both studies highlight the possibility of compensatory 
brain mechanisms underlying undetectable behavioural differences in working memory tasks 
in cannabis users. We propose that similar mechanisms could operate in ecstasy users.  
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EEG is an electrophysiological technique with high temporal resolution that may be 
beneficial to use in combination with behavioural measures to assess any changes in brain 
function as a result of ecstasy use in semantic retrieval. Event Related Potentials (ERPs) are 
ideal for investigating tasks that require executive control, as these tasks require rapid 
executive decisions that are less detectable with other neuroimaging techniques. Burgess et 
al., (2011) observed differences between ecstasy users and controls in ERPs in a word 
recognition task. Ecstasy users showed an attenuation of a late positivity over left parietal 
scalp sites despite equivalent performance on the task. As such this is suggested to be a 
durable abnormality in a specific ERP component associated with recollection in ecstasy 
users that may have not been detected with behavioural measures alone. 
The P3 ERP is a positive spike in neuroelectric activity that occurs around 300ms 
after stimulus onset. This component is thought to be involved in higher level cognitive 
processing and executive functioning. A diminished P3 potential is understood to reflect 
cognitive dysfunction. Casco et al. (2005) observed a diminished P3 response in a simple 
discrimination task in moderate and heavy ecstasy users compared to controls in a visually 
evoked potential study. Furthermore Gamma et al. (2005) report reductions in the P3 
amplitudes of ecstasy users, compared to controls in an inhibitory control (Go-Nogo) task.  
However it is reported that this effect is diminished after controlling for age, educational 
level and cannabis use. Indeed the authors suggested that the diminished P3 response could 
be a polydrug effect given the amount of cannabis use reported by the ecstasy users in their 
sample. de Sola et al., (2008) conducted a battery of cognitive tests to investigate P3 
differences between ecstasy users, cannabis users and controls, they found no significant 
between group differences on these tasks in P3 latency or amplitude. However there were 
significant correlations between P3 latency and lifetime cannabis use,  whereas Mejias et al., 
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(2005) report aberrations in the N2 component in ecstasy users compared to controls in a 
visual oddball task. 
The current study aims to characterise the nature of MDMA‟s effects on the cognitive 
processes involved in accessing semantic memory by using EEG measures during a semantic 
retrieval task similar to that used by Badre et al., (2005) and Whitney et al., (2010).  It is 
hypothesised that behavioural differences will not be present in trials where there is high 
association between the cue and target word, but that differences will be observed with 
weaker semantic associations, as the weaker association condition will be more difficult, 
requiring induction of the central executive.  Similarly it is hypothesised that there will be 
differences in electrophysiological measures that reflect higher level processing (e.g. P3, N2) 
whereby ecstasy users display aberrant electrophysiological behaviour compared to nonusers.  
 
Method: 
Design: 
In all analyses, a mixed design was used with a between groups factor of drug user group 
with 3 levels (ecstasy user, non-ecstasy polydrug user and drug naive controls) and 
associative strength (High vs. Low) as a within subjects factor. Mixed ANOVA was 
conducted on the behavioural data with the scores on the semantic association tasks as the 
dependent variable. ERP data was analysed using mixed ANOVA with drug user group as the 
between subjects factor and site of electrode (PO7, PO3, O1, OZ, POZ, PO8, PO4 and O2 for 
the N2 and P3 components and sites FZ, FCZ, FC1, FC2, CZ, C1 and C2 for the P2 
component) as well as associative strength (high vs. low) as the within groups factors. Mean 
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amplitudes at the 3 ERP components were the dependent variables. Where appropriate, 
significant main effects were further investigated using univariate ANOVA.  
Participants: 
Twenty ecstasy users (mean age = 23.95, SD = 0.57, 10 male), 20 non-drug user controls 
(mean age = 23.1, SD = 0.66, 7 male) and 20 non-ecstasy drug user controls (mean age = 
22.58, SD = 0.79, 9 male) were recruited via direct approach to university students and club 
goers. In terms of statistical power, with 20 participants in each of the three groups, the 
sample is sufficient to detect a difference between pairs of means of at least 1 standard 
deviation at alpha = .05 and beta =.20 (Hinkle et al., 1994). The additional control group of 
participants that have not used ecstasy previously, yet have used other illicit substances was 
recruited to address the issue of polydrug use as a potential cause for the cognitive deficits 
observed. 
To avoid age related deficits in working memory obscuring pharmacologically derived 
deficits age range for inclusion was 18-29 years. Inclusion in the ecstasy user group required 
participants to have taken ecstasy/MDMA on 5 or more occasions over their lifetime (actual 
minimum = 5 ecstasy tablets). Furthermore for inclusion in both control groups participants 
must have never used ecstasy/MDMA, however all other illicit substances were permitted for 
the non-ecstasy poly drug user control group. 
All participants were asked to abstain from consuming ecstasy for a minimum of 7 days prior 
to testing and urine samples were collected upon arrival to the lab for urinary analysis of all 
drug metabolites, to confirm abstinence (after ingestion MDMA is generally accepted to be 
detectable in urine for 1-3 days, this is the same for cocaine and amphetamines, with cannabis 
being detectable for anything up to 95 days Verstraete, 2004).  Participants were also 
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requested to abstain from use of other illicit drugs for a minimum of 24 hours prior to 
participating and ideally for 7 days. 
 
Materials 
Upon entering the lab participants completed a background drug use questionnaire, which 
provides the researcher with indices of drug use patterns and other lifestyle variables.  
Comprehensive details of ecstasy use as well as other illicit drug use were requested, such as 
first and last drug use, patterns of drug use, frequencies and doses over time. Using a method 
employed by Montgomery et al. (2005) estimates of total lifetime drug use of each drug were 
calculated. Totals for last 30 days drug use as well as weekly drug use estimates were also 
calculated. This questionnaire also sought information about health, age, years of education 
and perceived changes to mood and cognition amongst other lifestyle variables. 
Measures of Sleep Quality 
Sleep quality and alertness were measured to investigate any possible relationship between 
sleep quality and cognition using the following questionnaires; a sleep quality questionnaire, 
exploring typical quantities of sleep (how many hours slept typically, how many hours over 
the last 3 nights) and level of quality of sleep. The Epworth Sleepiness Scale (ESS, Johns, 
1991), explores the chances of dozing or falling asleep in various situations such as “sitting 
and reading” and “sitting quietly after lunch without alcohol”, and is scored from 0 = would 
never doze off to 3 = High chance of dozing. A high total score here is indicative of increased 
subjective daytime sleepiness. The Morningness-Eveningness Questionnaire – self 
assessment version (MEQ, Terman, Rifkin, Jacobs & White, 2001) is a self assessment of 
morningness-eveningness in human circadian rhythms (originally developed by Horne & 
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Östberg, 1976), a high score on this questionnaire is indicative of a morning type person and 
a low score is indicative of an evening type person. Finally the Karolinska Sleepiness Scale 
(Akerstedt & Gillberg, 1990), is a self assessment of sleepiness at the current moment in time 
(ranging from 1= extremely alert, to 9 = extremely sleepy, fighting sleep, effort to stay 
awake), therefore this can be administered at different time points of the experiment to assess 
sleepiness. As such this was administered to participants pre and post task. 
State Mood. 
State Anxiety, Arousal and Depression were measured using scales devised by Fisk & Warr 
(1996). Participants are required to rate on a 5 point likert scale from 1 = not at all, to 5 = 
extremely, how they are feeling at the time of testing.  A high score on each subscale 
indicates increased hedonic tone/anxiety/arousal.  
NASA-TLX (Hart et al. 1988) 
Finally, a questionnaire measuring subjective workload was given post task. This is a multi-
dimensional scale, consisting of six sub-scales (mental demand, physical demand, temporal 
demand, personal performance rating, effort and frustration). Participants were required to 
place a mark on a 100 mm line, indicating where they perceive their demand to be on the 
scale. These are taken to observe whether there are any differences between ecstasy users and 
non users in perceived cognitive demand on the task. It has been reported that ecstasy users 
may be more susceptible to stress than non-users and may thus report increased cognitive 
effort (Wetherell et al., 2012). 
Access to Semantic Memory 
The executive function “access” was assessed using a semantic association task that is based 
around the tasks used by Whitney et al. (2011) and Badre et al. (2005), whereby 2 types of 
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semantic judgement which differed in their level of difficulty (high association/low 
association) were used. In both difficulty levels participants were presented with a cue word 
in the centre of a computer monitor followed by three target words, one which had a semantic 
association with the cue, and two distracters. Participants had to decide which of the three 
target words had the strongest semantic association with the cue word. They selected their 
answer by pressing one of three buttons on a response box which corresponded to their 
position on screen. They were either high association between cue and target words (e.g. 
candle - flame) or low association (e.g. detective - search). The low association judgement is 
deemed to be more difficult and require more processing than the relatively automatic high 
association semantic judgements. As such the low association between cue and targets leads 
to a less obvious dissociation from distracters requiring recruitment of additional executive 
resources in the semantic network (Whitney et al., 2011). The stimuli used were matched for 
word length, frequency and cue-target association strength (Badre et al., 2005; Whitney et al., 
2011) and were kindly provided by Whitney et al. The task consisted of a practise round 
followed by 4 blocks of 30 trials, with both high and low association trial types appearing in 
each block pseudo-randomly (15 of each in each block). The cue word was presented for 1 
second in the centre of a computer screen. After this the three target words appeared below 
aligned to the left, centre and right of the monitor. Participants were instructed to respond via 
pressing a button on the response box corresponding to the position of the target on the screen 
(left, centre, right). The targets remained on screen until a response was made or until the trial 
timed-out (time out set to 8.5 seconds). An inter trial interval of 2 seconds was employed. 
The task took around 20 minutes to complete.  Participants were instructed to respond as 
quickly and as accurately as possible.  
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Equipment 
EEG was recorded using a 64 channel Biosemi Ag-AgCl active-two electrode system 
(Biosemi B.V, Amsterdam, Netherlands) with pin type electrodes mounted in a stretch-lycra 
headcap (Biosemi) and positioned according to the international 10-20 system. Neuroelectric 
activity was recorded from the following sites: frontal (FPz, FP1, FP2), anterior-frontal (AFz,  
AF3, AF4, AF7, AF8), frontal (Fz, F1, F2, F3, F4, F5, F6, F7, F8), frontocentral (FCz, FC1, 
FC2, FC3, FC4, FC5, FC6), central (Cz, C1, C2, C3, C4, C5, C6), temporal (FT7, FT8, T7, 
T8, TP7, TP8), parietocentral (CPz, CP1, CP2, CP3, CP4, CP5, CP6), parietal (Pz, P1, P2, P3, 
P4, P5, P6, P7, P8, P9, P10), occipitoparietal (POz, PO3, PO4, PO7, PO8) and occipital (Oz, 
O1, O2, Iz). Sigma electrolyte gel was used to ensure contact between scalp and electrodes.  
Vertical and horizontal electro-occulograms were recorded using bipolar, flat Ag-ACl 
electrodes positioned above and below the left eye as well as to the outer side of each eye.  
Data was digitized at a sampling rate of 512Hz and no filters were applied online so that the 
data could be visually inspected for noise and offline filtering could be performed.   
Procedure 
Testing sessions commenced at 9.30 a.m or 1.30 p.m, and equal numbers of participants from 
each condition were tested in the morning and the afternoon. Upon entering the lab, 
participants were given a brief description of the experiment and written informed consent 
was obtained. Following this, participants gave a urine sample which was immediately frozen 
at -25 Celsius. Participants then completed the battery of questionnaires, whilst their head 
circumference and other details were measured, and an electrode cap and electrodes were 
fitted.  The questionnaires were administered in the following order:  Background drug use 
questionnaire, Morningness-Eveningness questionnaire, sleep quality questionnaire, State 
Mood, Epworth Sleepiness Scale, Karolinska sleepiness scale (before) and fluid intelligence 
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was assessed using Raven‟s Progressive Matrices (Raven, Raven & Court, 1998). Following 
completion of these questionnaires, the EEG setup was checked and if necessary modified. 
Participants then completed the computerised task on a desktop computer running Inquisit 
version 3.0.6.0 (Millisecond Software, 2011). The NASA-TLX questionnaire was completed 
after the task as was the post task Karolinska sleepiness scale. Finally participants were fully 
debriefed and paid £20 in store vouchers. The study was approved by Liverpool John Moores 
University Research Ethics Committee, and was administered in accordance with the ethical 
guidelines of the British Psychological Society. 
 
 
EEG Analysis 
The EEG data was analysed using BESA 5.3 (MEGIS software GmbH, Gräfelfing, Germany).  
All recordings were visually analysed offline, using high and low pass filters of 0.1Hz and 40 
Hz respectively. Any channels judged to be bad were replaced by interpolation and all data 
were EOG-corrected using BESAs PCA based algorithm. All trials judged to be bad after this 
point were discarded. EEG was segmented into epochs from -500 to 1000 ms from time of 
stimulus onset. Epochs were time-averaged by stimulus type so that ERPs for correctly and 
incorrectly identified stimuli in each condition of each task (e.g. correct “high associations” 
and incorrect “high associations” and correct “low associations” and incorrect “low 
associations”) could be generated for each individual. Only ERPs for correct responses were 
included in the subsequent analysis. There were 120 trials in total, the mean number of good 
trials retained for grand averaging per subject was 109.66 (average of 8.6% rejected trials), 
after rejecting incorrect trials (6.1%) and those containing artefacts (2.5%).  Grand averages 
were made for each group (ecstasy user, polydrug user and drug naïve) on each condition 
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(correct “high associations”, correct “low associations”). The overall P3 response was 
defined as the mean amplitude between 280 and 350 ms, for the low association condition 
and 250-350ms for the high association condition. These time windows were centred on the 
positive peak latency and the duration was chosen due to this epoch containing the majority 
of positive activity for all conditions by observing topographic maps (See Figures 1 & 2).  
Electrode activity was analysed in this epoch from occipitoparietal and occipital electrodes 
PO7, PO3, O1, OZ, POZ, PO4, PO8 and O2, as the greatest amount of activity in the P3 
component could be observed at these sites. Further components were also analysed for 
between group differences, including the N2 and P2 components.  The N2 component was 
also largest over occipitoparietal and occipital electrodes (PO7, PO3, O1, OZ, POZ, , PO4, 
PO8 and O2) , between 120-190ms in the low association condition and 120-200ms in the 
high association condition, again epochs were based around the mean local negative peak at 
these sites and encompassed the majority of negative activity over all 3 groups. The P2 
component was most visible as a positive peak between 170 and 230ms (for both low and 
high association) at anterior and midline sites (FZ, FCZ, FC1, FC2, CZ, C1 and C2) the mean 
amplitudes at these sites from the epochs based around the peaks from the grand averages of 
all conditions were analysed. 
<<Insert Figures 1 & 2 About Here>> 
 
Urinary Analysis 
Frozen urine samples were delivered to University Hospitals Aintree and were analysed using 
Solid Phase Extraction (Mixed Mode Phase) followed by Reverse Phase HPLC MS/MS 
detection using BOTH Positive & Negative Ion Multiple Reaction Monitoring (MRM). Urine 
Specimens have been tested for: the Synthetic Cannabinoids (JWH-018, JWH-073, JWH-250, 
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JWH-398, JWH-122, JWH-019, AM-694, WIN 48098 & WIN-55212-2), as well as the 
„designer‟ drugs „Mephedrone‟, bk-MDMA or „Methylone‟, bk-MBDB or „Butylone‟, bk-
PMMA or „Methedrone‟, 1-benzylpiperazine, TFMPP, mCPP and MDPV. Also tested for 
were a series of 12 Piperazine compounds, 4 β-Keto Amphetamines, a series of 11 
Methcathinone compounds, 4-Fluoroamphetamine, Bupropion & the Hallucinogenic 
Amphetamines: D.O.B. („bromo-STP‟ or „Brolamphetamine‟), D.O.C. and D.O.I. Finally, 
„traditional‟ drugs of abuse: Amphetamine(s) including M.D.M.A., M.D.A. & M.D.E.A., 
Barbiturates, Benzodiazepines, THC & Cannabinoids, Buprenorphine, Cocaine & metabolites, 
Methadone & metabolites, Opiates & Opioids (Morphine, Codeine, Dihydrocodeine, 
Tramadol, d-Propoxyphene, Oxymorphone & Oxycodone), LSD, G.H.B. (and the Lactone 
Precursor), Psilocybin, Ketamine and Methaqualone were tested for as well. 
Results 
Table 1 shows indices of ecstasy use from the ecstasy user group, including total lifetime 
dose (tablets), total number of tablets taken in the last 30 days and frequency of use (times 
per week). 
<<Insert Table 1 Here>> 
Participants‟ socio-demographic information, state mood scores from the mood adjective 
checklist and sleep measures are shown in Table 2, and indices of other drug and alcohol use 
are displayed in Table 3.  
<<Insert Tables 2 & 3 Here>> 
One way ANOVA revealed that there were no significant between group differences on 
measures such as age, average hours sleep per night, total score on the Epworth Sleepiness 
Scale, Morningness-Eveningness questionnaire total score, post test Karolinska sleepiness 
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scale, levels of arousal, depression and anxiety or total score on Ravens Progressive Matrices.  
However there were between group differences in the pre testing Karolinska sleepiness scale 
(i.e. how sleepy the participants felt before the test battery) F(2, 58) = 3.78, p<0.05, planned 
comparison t-tests revealed that the ecstasy user group felt significantly more sleepy prior to 
testing than the polydrug control group t(38)=2.39, p<.05, but not the drug naïve control 
group  t(37) = 0.50, p>.05. 
t-tests between the ecstasy user group and the polydrug-non-ecstasy group revealed that the 
ecstasy user group had a significantly larger lifetime total of joints smoked than the non 
ecstasy drug users (5057.88 compared to 1091.71) t(17.88) = 2.02, p<.05 (Levene‟s test was 
significant so degrees of freedom have been adjusted accordingly). The ecstasy users had also 
smoked significantly more joints within the last 30 days (32.77 compared to 6.09) t(16.01) = 
1.86, p<.05. There were however no differences between these two groups on other drug 
intake variables.  However as can be seen from Table 3, the ecstasy user group can be 
described as polydrug users. 
Urinary Analysis 
The metabolites detected in the urinary analysis are displayed in Table 4.  
<<Insert Table 4 Here>> 
Drug metabolites detected were restricted to cannabinoids, TFMPP and BZP, and were 
relatively low level. Exclusion of participants with cannabinoid metabolites in their urine did 
not change the behavioural or electrophysiological analyses so analyses reported include 
these participants.  
 
Behavioural Data Analysis 
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The semantic association was programmed in Inquisit version 3.0.6.0 (Millisecond software, 
2011) and was analysed using SPSS (17). Incorrect answers in each case were given a score 
of 0 and were not investigated any further for reaction time analysis. Mean reaction times 
were calculated for correct high association trials as well as correct low association trials. 
Reaction time data reduction involved excluding reaction times less than 200ms and greater 
than 5000ms as these reaction times represent pre-emptive responding and a loss of 
concentration respectively. Furthermore individual trial reaction times that were more than 3 
standard deviations above the individual mean were discarded. The mean percentage of 
outliers that were discarded from each group were; ecstasy users 1.46 (±0.66), polydrug users 
1.42 (± 1.05), drug naïve 1.71 (±0.92), there were no between group differences in amount of 
outliers F (2, 57) = 0.63, p>.05, 
Performance on the semantic retrieval task was measured both in terms of number of errors 
made (incorrect responses) and reaction time. A mixed ANOVA was conducted with between 
subjects factor of group and within subjects factor of difficulty (high association and low 
association). Using error count as the dependent variable there was no significant effect of 
difficulty F(1, 57) = 0.04, p>.05 (sphericity assumed), no main effect of group F(2, 57) = 
1.56, p>.05 and no group by difficulty interaction F(2, 57) = 0.01, p>.05 (Table 5). Similarly 
using reaction time as the dependent variable no significant between group differences were 
observed F(2, 57) = 0.07 p>.05. Difficulty and group by difficulty interactions were non 
significant p>.05 in both cases (Table 5).  
Post task NASA TLX scores were analysed using a multivariate analysis of variance 
MANOVA. This revealed no overall between group differences in perceived demand F (12, 
104) = 0.94, p>.05 for Pillai‟s trace, nor any between group differences on the individual sub-
scales of their subjective perception of subjective workload (Mental demand; F(2, 56) = 1.06, 
p>.05, Physical demand; F(2, 56) = 0.10, p>.05, Temporal demand; F(2, 56) = 1.56, p>.05, 
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Effort; F(2, 56) = 0.48, p>.05, Performance; F(2, 56) = 2.62, p>.05, Frustration; F(2, 56) = 
0.77, p>.05)  . 
ERP analysis 
The grand average waveforms for each group (users, polydrug non-users and drug naïve 
controls) can be observed for electrodes PO7, PO3, O1, OZ, POZ, PO8, PO4 and O2  in 
Figure 3 (high association) and Figure 4 (low association). Mean amplitudes for each 
condition and electrode are given in Table 6. Due to some unusable EEG data, 1 participant is 
excluded from statistical analysis on the EEG data, from the drug naïve group (n=19). 
A mixed ANOVA, with between subjects factor of group and within subjects factors 
of difficulty (high association and low association) and site (FZ, FCZ, FC1, FC2, CZ, C1 and 
C2) was conducted on the mean amplitudes across the epochs measured (170-230ms in both 
conditions) for the P2 component. This revealed, no main effect of difficulty F(1, 56) = 0.32, 
p>.05, no difficulty by group interaction F(2, 56) = 0.35, p>.05, no main effect of site F(4.21, 
236.03) = 5.22, p>.05, no site by group interaction F(8.43, 236.03) = 0.26, p>.05, no 
difficulty by site interaction F(4.85, 271.44) = 0.51, p>.05 and no difficulty by site by group 
interaction F(9.69, 271.44) = 0.48, p>.05 (degrees of freedom adjusted in line with 
Greenhouse Geisser statistic in all cases). Between group differences were also non-
significant F(2, 56) = 1.68, p >.05.  
A mixed ANOVA, with between subjects factor of group and within subjects factors 
of difficulty (high association and low association) and site (PO7, PO3, O1, OZ, POZ, , PO4, 
PO8 and O2) for the mean amplitudes across the epochs measured (120-190 ms in the low 
association condition, 120-200ms in the high association condition) on the N2 component 
revealed no main effect of difficulty F(1, 56) = 1.05, p>.05, no difficulty by group interaction 
F(2, 56) = 0.04, p>.05, no main effect of site F(3.82, 213.92) = 6.37, p>.05, no site by group 
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interaction F(7.64, 213.92) = 1.10, p>.05, no difficulty by site interaction F(4.78, 267.40) = 
0.81, p>.05 and no difficulty by site by group interaction F(9.55, 267.40) = 0.73, p>.05 
(degrees of freedom adjusted in line with Greenhouse Geisser statistic in all cases). Between 
group differences approached significance F(2, 56) = 2.78, p = .07. In line with apriori 
predictions and to further explore this trend on the N2 component, Helmert contrasts were 
performed. The Helmert contrasts revealed a significant difference between the ecstasy 
polydrug user group and the drug naïve participants, Contrast estimate = -2.10, p<.05. 
Consequently, univariate ANOVA was conducted between drug naïve participants and 
ecstasy polydrug users alone, with amplitude at each site as the dependent variable to explore 
the significant contrast. In the low association condition significant differences were observed 
at electrode site O1 F(1,37) = 3.37, p<.05; site OZ F(1,37) = 3.41, p<.05; PO8 F(1,37) = 6.32, 
p<.01; PO4 F(1,37) = 3.42, p<.05 and O2 F(1,37) = 7.02, p<.01. In the high association 
condition significant differences were observed at site PO3 F(1,37) = 3.62, p<.05; OZ F(1,37) 
= 5.05, p<.01; POZ F(1,37) = 2.83, p<.05; PO8 F(1,37) = 5.56, p<.01; PO4 F(1,37) = 2.84, 
p<.05 and O2 F(1,37) = 4.17, p<.05. In all cases, ecstasy users showed a greater negativity 
than drug naïve controls (Table 6). 
A mixed ANOVA, with between subjects factor of group and within subjects factors 
of difficulty (high association and low association) and site (PO7, PO3, O1, OZ, POZ, , PO4, 
PO8 and O2) on the P3 component for the mean amplitudes across the epochs measured 
(280-350 ms in the low association condition, 250-350 ms in the high association condition) 
revealed no main effect of difficulty F(1, 56) = 0.71, p>.05, no difficulty by group interaction 
F(2, 56) = 0.60, p>.05, no main effect of site F(4.18, 233.99) = 13.97, p>.05, no difficulty by 
site interaction F(3.42, 191.64) = 1.56, p>.05 and no difficulty by site by group interaction 
F(6.84, 191.64) = 0.61, p>.05. However there was a significant site by user group interaction 
F(8.36, 233.99) = 1.65, p≤.05 (degrees of freedom adjusted with Greenhouse Geisser statistic 
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in all cases). There were no significant between group effects F(2, 56) = 0.74, p>.05, so these 
were not investigated further. To further explore the site by user group interaction, a series of 
univariate ANOVAs were run with group as the between groups variable and amplitude at the 
various sites as the dependent variable. This yielded no significant differences between the 
three groups and no significant post hoc comparisons, p>.05 in all cases.  
Discussion 
The current study investigated the executive function of access to semantic memory and its 
behavioural and electrophysiological correlates. Background variables such as fluid 
intelligence, age, measures of sleep, level of arousal, depression and anxiety showed no 
significant differences between the three groups. There were no behavioural differences 
between groups in terms of number of errors on task and reaction time to correct responses.  
Furthermore ecstasy users did not differ significantly to the control groups with respect to 
subjective mental workload. 
The electrophysiological data provide support for abnormal executive functioning in 
ecstasy-polydrug users. In the N2 component, although there were no main effects of 
difficulty or site, or any interactions with these and group, or difficulty by site by group, there 
were between group trends that warranted further exploration. In the low association 
condition of the task ecstasy users displayed a significantly larger negativity in the N2 (120-
200ms) component compared to drug naïve controls in occipital electrode sites O1, O2 and 
OZ  and occipitoparietal electrode sites PO8 and PO4 compared to drug naïve controls (Fig. 
4), although non-ecstasy polydrug users did not differ from either group.   
The supposedly easier “high association” condition showed significant differences in 
negativity at the N2 component in ecstasy users compared to drug naïve controls at occipital 
electrode sites OZ and O2, as well as occipitoparietal sites PO2, PO3, PO4 and PO8 (Fig. 3). 
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Components that reflect positivities (P2 and P3) showed no main effects of difficulty or site, 
or any interactions with these and group, or difficulty by site by group (except in P3 where 
there was a site by group interaction) and there were no between group differences. Thus 
these components are less informative about access to semantic memory in ecstasy users.  
However, the group difference in the N2 component does provide some interesting points to 
consider. 
The N2 component has been reported as having a source in the anterior cingulate 
cortex (Bekker et al., 2005; Nieuwenhuis et al., 2003; Van Veen & Carter, 2002) and to 
reflect neural processes engaged during conflict monitoring, thus being increased in high 
conflict trials (Yeung & Cohen, 2006), for example when incongruence between targets and 
cues/distracters elicits a conflict of response in a Stroop task (Kopp et al., 1996). Firstly, 
considering why the N2 was more pronounced in ecstasy users compared to drug naïve 
controls in those trials where there was a lower semantic association between target and cue 
words, it is possible that at this level of processing, the ecstasy users required the recruitment 
of additional resources in order to access the semantic network of long term memory 
compared to drug naïve controls. Previous research has provided evidence that ecstasy users‟ 
performance can be more greatly impaired under higher task difficulty. For example 
Montgomery et al., (2005) observed a decline in performance in a word fluency task when 
more rules were imposed, suggesting that deficits are more prominent in tasks that place 
more demand on the central executive. Moreover, given that participants reported no 
perceived differences in cognitive effort on the NASA-TLX it is possible that compensatory 
cognitive processing at neurological sites is correcting for deficits in executive function to 
eradicate behavioural differences and other research reporting null results, with respect to 
performance may reflect similar reallocation of cognitive resources. This aspect of the results 
was in line with our predictions.  
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However ecstasy users also displayed a greater negativity compared to drug naïve 
controls in the high association condition of the task, suggesting perhaps that is controlled 
processing in general that is impaired regardless of task difficulty.  It is generally accepted 
(Jefferies et al., 2004; Rossell et al., 2001; Shiffrin & Schneider 1977) that information 
processing involves two modes of processing; automatic and controlled. Controlled 
processing, unlike automatic processing, involves selectively and consciously attending to a 
stimulus, suggesting that controlled processing involves higher level mental processes. As 
such, automatic processing is proposed to rely on long-term memory, whilst controlled 
processing loads more on working memory (Jeffries et al. 2004), suggesting separable neural 
substrates. Indeed Rossel et al., (2001) used fMRI to investigate differences in effortful and 
automatic processing in a similar lexical decision priming experiment, and found that distinct 
sub regions of the anterior cingulate cortex showed activation dependent on the processing 
type involved. The N2 component in a semantic classification task was argued to reflect 
controlled processing by Ritter et al. (1982). Perhaps any early automatic processing (such as 
that observed in the P2 component), is unaffected by drug use, whereas such higher level 
controlled processes are more affected. Indeed perhaps the N2 is the earliest stage at which 
controlled processing is detectable, and recruitment of additional resources at this stage could 
offset any further modulation of the waveform in later components such as the P3. 
Consequently, while we hypothesised that controlled processing and recruitment of the 
central executive would be elicited only in the low association condition, based on the results 
it is likely that the task was demanding enough to recruit executive resources in both 
conditions.  
While the above discusses possible N2 related differences in access to semantic 
memory, it is indeed possible that the N2 in the present study reflects changes in other 
cognitive processes additional to semantic access (See Folstein & van Petten, 2008, for 
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review). The N2 in the present study was prominent in more posterior electrodes which 
Suwazono et al. (2000) suggest is reflective of increased attention demands in the visual 
cortex required for stimulus processing. In this study, posterior N2 was eliminated by 
eliminating target novelty (i.e. making targets completely predictable). Moreover Luck and 
Hillyard (1994) investigated subcomponents of the N2 component using visual search tasks. 
It was found that the bilateral posterior N2 as seen in the present study was related to visual 
search and target probability, with an increased posterior N2 when participants could not 
predict a target before presentation. Taken together this provides tentative evidence that in the 
present study the posterior N2 may reflect increased demands on visual search and 
maintenance of visual representations, with greater negativity in ecstasy polydrug users 
showing that they require increased attentional resources for this.    
As with most studies on cognitive deficits relating to ecstasy use, there are some 
limitations which necessitate a degree of caution when interpreting the data. For example, 
despite controlling for the use of other drugs, by introducing a polydrug control group 
(namely cannabis users) that had never taken ecstasy, the ecstasy users in this study smoked 
significantly more cannabis that the polydrug group. The ecstasy user group also reported 
consuming more cocaine than the polydrug group. As such any observed differences could 
still be attributed to the use of these other drugs, or indeed a synergistic effect of concomitant 
use of other drugs.  Perhaps any effects here could be better described as a result of polydrug 
use, especially given that ecstasy users, although showing greater negativities in the N2 in 
both conditions of the task, compared to drug naïve controls were not significantly different 
to polydrug controls.  
Studies that employ quasi-experimental designs cannot exclude the chance that 
individual differences may belie any observable effect other than drug use. We attempted to 
control for many of these individual differences, such as sleep quality, fluid intelligence and 
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levels of arousal, depression and anxiety. Another limitation lies in self reports of background 
drug use, which may not be completely accurate due to the problematic recall of drug users.  
However this is the most appropriate method of investigating drug use and executive function, 
given the legal status of the drug. Moreover this method is commonly used in the literature 
(Fox et al., 2001; Montgomery et al., 2005; Montgomery et al., 2010). The purity of the 
ecstasy tablets consumed, as well as the cocaine purity and cannabis strength are all 
questionable and cannot be guaranteed. However Parrott (2004) reported that the ecstasy 
tablets collected from amnesty bins in nightclubs in the UK was approaching 100% purity. If 
this is incorrect however, and the purity is in fact, much lower, perhaps this raises additional 
concerns about the cognitive effects observed (Montgomery et al., 2010). 
The present study provides evidence for changes in electrophysiology in 
ecstasy/polydrug users. Durable abnormalities of the N2 component observed over occipital 
and occipitoparietal sites of drug users compared to drug naïve controls is suggestive of 
compensatory mechanisms, or reallocation of cognitive resources that are deployed to 
attenuate any observable behavioural differences caused by ecstasy related disturbances to 
traditional processing of semantic information and allocation of attention during visual search. 
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Table 1 – Indices of ecstasy use 
Variable Mean S.D 
Total tablets 177.65 301.73 
Last 30 days total 0.6 2.26 
Frequency of use (times per 
week) (n=12) 
0.24 
 
0.42 
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Table 2 – Indices sleep quality, fluid intelligence and socio-demographic variables 
 Ecstasy 
Users 
 
  Polydrug 
(non-
ecstasy) 
  Drug 
Naïve 
Controls 
  
Males:  n, % 10 (50)   9 (45)   7 (35)   
 Mean SD  Mean SD  Mean SD  
 
Age 
 
23.94 2.50  22.58 3.45  23.10 2.94  
University 
degree: n 
(%) 
14 (70)   12 (60)   11 (55)   
          
Employment 
status 
         
Student;  n, 
(%) 
12 (60)   14 (70)   17 (85)   
Employed; n 
(%) 
4 (20)   4 (20)   3 (15)   
Unemployed
; n (%) 
4 (20)   2 (10)   0 (0)   
          
Ravens 
Progressive 
Matrices 
(maximum 
60) 
48.68 5.96  48.35 5.83  51.35 5.01  
          
Sleep – 
Hours/night 
 
7.13 1.91  7.8 1.39  7.05 1.16  
ESS Score 
(maximum 
24) 
 
6.5 3.3  6.7 3.15  6.5 3.32  
KSS before 5.05 1.93  3.75 1.48  4.79 1.23  
          
KSS after 6.53 2.03  5.85 1.53  6.56 1.46  
          
MEQ total 42.10 10.1
5 
 45.70 9.40  47.90 8.30  
          
State anxiety 11.4 4.08  12.44 2.18  11.75 2.12  
          
State arousal 19.7 4.54  20.5 3.68  20.1 3.02  
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State 
depression  
13.1 3.91  12.61 2.4  12.1 3.14  
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Table 3: Indices of drug use other than ecstasy 
 
 
  
 Mean SD n Mean SD n Mean SD n 
 
Cannabis 
         
 Frequency 
(times/wk) 
2.67 3.24 12 0.95 1.9 13 - - - 
 Last 30 
days 
(joints) 
32.77 53.75 15 6.09 15.34 17 - - - 
 Total use 
(joints) 
5057.88 7504.30 16 1091.71 2531.65 19 - - - 
Age at 1
st
 
use 
         
          
Cocaine           
Frequency 
(times/wk) 
0.15 0.14 11 0.27 0.34 2 - - - 
Last 30 
days 
(lines) 
0.4 1.12 15 1.60 3.58 5 - - - 
Total use 
(lines) 
813.97 1940.19 16 107.30 208.43 5 - - - 
Age at 1
st
 
use 
         
          
Ketamine          
Frequency 
(times/wk) 
0.26 0.42 5 0.02 - 1 - - - 
Last 30 
days use 
(grams) 
1 2.65 9 - - - - - - 
Total use 
(grams) 
31.26 70.61 11 1.13 1.62 3 - - - 
Age at 1
st
 
use 
         
          
Alcohol 
units p/w 
 
15.33 15.29 20 10.53 8.37 20 9.93 11.58 20 
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Table 4: Amounts of various drug metabolites found in urine samples (mg/L) 
 
 
 THC ∆9 THC 11-hydroxy-∆9-THC 1-Benzylpiperazine TFMPP 
E user N 3 3 3 1 1 
 Mean 0.0083 0.16 0.003 0.84 0.18 
 SD 0.01185 0.18286 0.00346 - - 
Polydrug N 1 1 1 - - 
 Mean 0.001 0.41 0.0020 - - 
 SD - - - - - 
Drug 
Naive 
N - - - - - 
 Mean - - - - - 
 SD - - - - - 
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Table 5: Performance Data (means and SDs of error count and reaction times) for all 
participants in both conditions. 
 
 
 
Ecstasy 
users 
 Polydrug 
(non 
ecstasy) 
 Drug 
Naive 
 
 Mean SD Mean SD Mean SD 
 
High 
association 
errors 
 
 
4.00 
 
 
2.34 
 
 
4.60 
 
 
2.78 
 
 
 
5.25 
 
 
2.77 
 
Low 
association 
errors 
 
 
4.10 
 
 
2.57 
 
 
4.60 
 
 
2.09 
 
 
5.35 
 
 
2.92 
 
High 
association 
RT (ms) 
 
 
1282.26 
 
 
255.91 
 
 
1294.43 
 
 
354.77 
 
 
1209.39 
 
 
230.89 
 
Low 
association 
RT (ms) 
 
 
1265.14 
 
 
250.85 
 
 
1294.21 
 
 
 
308.44 
 
 
1180.39 
 
 
198.60 
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Table 6: Mean amplitudes across components, for each electrode measured. 
 
 
 
 
User group P3 High Association 
 PO7           PO3           O1              Oz            POz          PO8           PO4          O2 
Ecstasy user (20) 2.95 (4.02)     3.94 (2.42)      2.76 (3.01)     1.60 (3.24)     4.19 (2.34)     4.40 (3.23)     4.94 (2.99)     3.31 (3.59) 
Polydrug (20) 4.12 (2.83)     2.97 (2.57)      3.52 (4.60)     3.04 (3.40)     3.28 (2.27)     5.72 (3.78)     4.05 (3.27)     3.32 (3.32) 
Drug Naïve (19) 3.62 (3.19)      3.92 (2.39)     2.84 (3.17)     2.13 (3.14)     3.42 (2.56)     5.35 (3.40)     4.00 (2.21)     3.27 (2.75) 
 P3 Low Association 
Ecstasy user (20) 3.48 (3.74)     4.60 (2.74)     2.32 (3.57)     1.79 (2.90)     4.46 (2.40)     3.78 (2.92)     4.98 (3.33)     2.97 (3.39)    
Polydrug (20) 4.16 (3.29)     3.44 (3.16)     2.27 (4.40)     2.70 (2.85)     3.89 (2.26)     5.92 (4.61)     4.41 (3.67)     3.14 (3.90) 
Drug Naïve (19) 4.32 (3.42)     4.40 (2.64)*    3.08 (3.46)     2.22 (3.21)     3.93 (2.80)     6.07 (3.32)    4.54 (2.69)     3.78 (2.92)      
 N2 High Association 
Ecstasy user (20) -1.66 (3.41)    -1.32 (3.55)    -2.19 (3.53)    -2.51 (3.45)    -0.70 (4.01)   -1.41 (3.20)   -1.04 (3.69)    -2.17 (4.12) 
Polydrug (20) -2.06 (4.57)    -2.37 (2.90)*    -2.41 (4.36)    -0.59 (4.19)    -0.58 (2.42)   -0.09 (4.11)   -0.44 (2.57)    -1.15 (3.44) 
Drug Naïve (19) -0.58 (3.11)    0.67 (2.95) *    -0.36 (3.43)     0.09 (3.78)     1.22 (3.03)     1.12 (3.50)     0.82 (3.19)    0.33 (3.51)    
 N2 Low Association 
Ecstasy user (20) -1.40 (3.55)    -0.95 (3.76)    -2.76 (4.19)   -1.98 (3.57)    -0.17 (3.62)    -1.56 (3.53)*    -1.01 (3.67)   -2.40 (3.75)* 
Polydrug (20) -1.69 (4.69)    -1.55 (3.15)    -2.11 (4.47)   -1.09 (3.43)    -0.28 (2.16)    -0.22 (4.02)    -0.29 (1.91)   -0.10 (3.71) 
Drug Naïve (19) 0.01 (3.67)      0.65 (2.97)    -0.33 (4.07)    -0.99 (3.62)     1.55 (2.91)     1.30 (3.58)*     0.91 (2.73)     0.67 (3.48)* 
 P2 High Association 
 Fz              FCz            FC1           FC2            Cz            C1             C2 
Ecstasy user (20) 0.55 (2.15)     1.49 (2.04)     1.15 (1.79)      0.86 (2.09)     1.91 (1.48)     0.89 (2.13)     0.77 (1.53)      
Polydrug (20) 1.07 (1.98)     1.85 (1.54)     1.28 (1.52)      1.05 (1.87)     1.53 (1.73)     0.87 (1.87)     0.40 (1.64)      
Drug Naïve (19) -0.10 (2.43)     0.78 (2.43)    0.61 (1.45)     0.03 (2.75)     0.59 (2.78)      0.22 (2.03)      -0.22 (2.72)      
 P2 Low Association 
Ecstasy user (20) 0.87 (2.59)     1.64 (2.39)     1.33 (2.54)    0.83 (2.75)      1.55 (1.97)     1.06 (1.45)     0.93 (1.40)     
Polydrug (20) 0.51 (1.42)     1.72 (1.62)    1.49 (2.81)     0.98 (1.74)      1.38 (1.77)     0.88 (1.99)     0.62 (1.79)     
Drug Naïve (19) 0.14 (1.90)     0.72 (2.16)    0.54 (1.98)     0.41 (1.79)      0.81 (2.41)      0.39 (2.22)    0.54 (1.97)     
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Figure 1. Topographies at midpoints for each component (P2, N2 and P3) in the high 
association condition. 
 
 
 
Fig. 1 Shows the topographies for the central point of each component, note that this is from grand averages of 
each group combined.  a) Shows the topography of activity in the epoch specified for the P2 component, note 
that this component has been isolated at an epoch where there is the most positivity displayed at midline/anterior 
electrodes b) shows a negativity in N2 notably around posterior and occipital electrodes and c) shows positivity 
in the P3 component similarly around posterior and occipital electrodes. 
 
 
 
 
 
 
 
 
 
 
 
 
a) P2 
200ms 
b) N2 
160ms 
c) P3 
315ms 
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Figure 2. Topographies at midpoints for each component (P2, N2 and P3) in the low 
association condition. 
 
 
 
Fig. 2 Showing the topographies for central points of each component, note that this is from grand averages of 
each group combined.  a) Shows the topography of activity in the epoch specified for the P2 component, b) 
shows a negativity in N2 notably around posterior and occipital electrodes and c) shows positivity in the P3 
component similarly around posterior and occipital electrodes. 
  
a) P2 
215ms 
b) N2 
200ms 
c) P3 
315ms 
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Figure 3. Grand average waveforms for the 3 groups across electrodes: PO3, POz, PO4, PO7, 
PO8, O1, Oz and O2 on the high association condition of the task. 
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Fig. 3 Depicts the grand average waveforms for each user group from each electrode measured (for the N2 and 
P3 components) for the high association condition of the task.  As such the time course of the various 
components can be observed..  (ecstasy users shown in blue, polydrug users in green and drug naïve controls in 
black). Also the magnitude and time course of the significant differences in mean amp in the N2component 
(120-200ms) between ecstasy users and drug naïve controls can be observed in PO3, POz, PO4, PO8, Oz and 
O2. Epochs showing significant differences in the N2 component are emboldened in black on the x axis. 
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Figure 4. Grand average waveforms for the 3 groups across electrodes: PO3, POz, PO4, PO7, 
PO8, O1, Oz and O2 on the low association condition of the task. 
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Fig. 4 Depicts the grand average waveforms for each user group (ecstasy user in blue, polydrug users in green 
and drug naïve controls in black) from each electrode measured (for N2 and P3 components) for the low 
association condition of the task. The magnitude and time course of the significant differences in mean amp in 
the N2component (120-190ms) between ecstasy users and drug naïve controls can be observed in PO4, PO8, O1, 
Oz and O2.  Epochs showing significant differences are emboldened in black on the x axis. 
 
